Modern therapy strategies focus on replication control with nucleos(t)ide analogs (NA) or interferons (IFN) in patients with chronic HBV infection to prevent end-stage liver disease (ESLD) in terms of cirrhosis and hepatocellular carcinoma (HCC) [2]. The gene discussed is IFNA1; the disease is hepatocellular carcinoma.